Comparison 5. Abatacept versus placebo (by study eligibility criteria).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 ACR 20% improvement	5		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 MTX failures	3	1138	Risk Ratio (M‐H, Fixed, 95% CI)	1.68 [1.48, 1.91]
1.2 Biologic failures	2	510	Risk Ratio (M‐H, Fixed, 95% CI)	2.27 [1.67, 3.07]
2 ACR 50% improvement	5		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 MTX failures	3	1138	Risk Ratio (M‐H, Fixed, 95% CI)	2.38 [1.89, 3.00]
2.2 Biologic failures	2	510	Risk Ratio (M‐H, Fixed, 95% CI)	2.96 [1.67, 5.25]
3 ACR 70% improvement	5		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 MTX failures	3	1138	Risk Ratio (M‐H, Fixed, 95% CI)	3.16 [2.12, 4.71]
3.2 Biologic failures	2	510	Risk Ratio (M‐H, Fixed, 95% CI)	7.05 [1.98, 25.14]